Teplizumab drug to delay type 1 diabetes to be rolled out on the NHS
The NHS in England and Wales has approved the use of Teplizumab, the first immunotherapy drug capable of delaying the onset of type 1 diabetes. The treatment can provide patients with three additional years before requiring lifelong insulin therapy, offering a significant reprieve for children and young people at risk.
Why it matters
This development represents a major medical milestone that could fundamentally change the management of type 1 diabetes, reducing the long-term burden of the disease for hundreds of families annually.
Image source, Family photo Image caption, Theo Sebastian-Jenkin was diagnosed with type 1 diabetes as a young boy after displaying extreme fatigue, weight loss and other symptoms
The article provides a straightforward, factual report on a medical development, relying on quotes from health bodies and patient advocacy groups without injecting political or ideological commentary.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in